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PRICE INDEXES FOR ACUTE PHASE TREATMENT OF DEPRESSION2
by Ernst R. Berndt, Susan H. Busch and Richard G. Frank
“It is not well to sneer at political economy in its
relation to the insane poor.  Whether we think it right or
not, the question of cost has determined and will
continue to determine their fate for weal or woe.”
(Asylum Superintendent George Cook, 1866)
I.  INTRODUCTION
Much has been written in the last decade on broad trends in medical care spending in
the US.  Although the most recent evidence is somewhat ambiguous, the apparent slowdown in
the rate of increase in aggregate health expenditures over the last five years has been welcomed by
many governments, employers, patients and insurers.  Relatively little attention, however, has
focused on components of the change in expenditures.  Is the trend change in medical care
expenditures due to changes in price, quantity, quality or a combination of all three?  What has
been the role of organizational change, such as the growth of managed care, relative to
technological/pharmaceutical innovation, such as new medications, on expenditure trends?
A standard procedure for economists analyzing changing expenditures over time is to
employ official government price indexes, divide nominal expenditures by such a price index, and
thereby decompose expenditures into price and quantity components.  Further analysis might then
focus on factors affecting real quantity growth, such as productivity gains.
In fact, the BLS’ medical Consumer Price Index (CPI) is often used by analysts
interested in undertaking such expenditure decompositions.  It is well known that such a practice
is frequently inappropriate and misleading, for the medical CPI deals only with consumers’ direct
out of pocket payments, and does not include payments from employers to insurers.
A deeper issue, however, involves the conceptual foundations underlying the medical
CPI and Producer Price Indexes (PPIs).  Although some revisions are gradually being
implemented, currently the BLS price indexes are based on the repricing over time of a fixed3
bundle of inputs.  For decades, health economists have argued that a more appropriate price index
is one based on the entire episodic treatment of selected illnesses and conditions, incorporating
technological and institutional innovations that change the mix of inputs used to treat the
condition, and including any effects on changed medical outcomes.
Developing a price index in health care can be viewed in terms of the unique
characteristics of the health services in question.  Consider creating a price index for a good that
displays the following features:
¤ Consumers pay only a portion of the gross price due to insurance.  The insurance
is associated with moral hazard resulting in “too much” use of the good.
¤ There has been dramatic technical change and great advances in the benefits
offered by the good.  Yet, the full range of benefits are difficult to measure.
¤ There is great variety in the forms that the good takes and consumers value those
forms differently.
¤ The supply side of the market for the good has experienced fundamental changes
in its organization.
¤ The good is viewed as so important in some cases that the government compels
people to use it.
The treatment of major depression, one of the most prevalent and disabling mental disorders,
exhibits all of the features listed above.  In this paper we report on the first three years of a
research program aimed at measuring prices and output for the treatment of this important
disease.  The approach taken in this program of research builds on several recent efforts to
construct price indexes for medical care.  That recent research includes work by Cutler,
McClellan, Newhouse and Remler [1996] that contrasts input price indexes for the treatment of
heart attacks that rose by 6.7% per year over 1983-94, with an outcomes adjusted index that
takes into account a conservative valuation for the extension of life expectancy attributable to new
heart attack treatments and increases by only 2.3% per year, implying a net bias of 4.4% annually.
Focusing on a price index for cataract surgery, Shapiro and Wilcox [1996] find that a CPI-like4
fixed weight input-based index increases by a factor of about nine between 1969 and 1993,
whereas their preferred alternative index incorporating realized reductions in hospital lengths of
stay, but ignoring any improvements in the quality of medical outcomes, increases by only a factor
of three, implying an annual differential of 4.6%.
Because depression is a chronic recurring illness and mortality is not an end point, we
must rely on indirect methods of incorporating information on clinical effectiveness and outcomes.
In our research we have made use of results from the published clinical literature, and from official
treatment guideline standards, to identify therapeutically similar treatment bundles that can then be
linked and weighted to construct price indexes for treatment of specific forms of major
depression.  Preliminary results from this research have been published in Frank, Berndt and
Busch [1998] and Frank, Busch and Berndt [1998].
In this paper we consolidate our findings, and extend our analysis considerably.
Specifically, we refine our definition of eligible treatment episodes, develop new imputations for
missing data, expand the set of treatment bundles from five to seven, and estimate hedonic price
regressions.
We begin the paper with an overview of current BLS procedures for constructing
medical care price indexes, and then provide a background on the nature of and alternative
treatments for acute phase major depression.  We outline features of the retrospective medical
claims data base from MEDSTAT, and then discuss our implementation of treatment episode
definition and identification.  We then report on quantities and prices of the treatment bundles
from 1991 to 1995, we construct and interpret CPI-like and PPI-like aggregate price indexes, and
we comment on an initial analysis involving hedonic price procedures.  We end the paper with a
discussion section, followed by concluding remarks.
II.  CURRENT PROCEDURES FOR MEASURING MEDICAL CARE PRICE INDEXES
In the US context, it is useful to distinguish “supply” and “demand” prices for medical
care.  By supply prices we mean the total payments received by health care providers for a5
particular medical treatment, consisting of the sum of payments from health insurance plans (both
private and public) plus that from patients’ direct out-of-pocket payments (OOPPs).  At this level
of generality, our supply price concept relates to components of the Producer Price Index (PPI)
published by the Bureau of Labor Statistics (BLS).
The demand price notion we employ here is the consumers’ direct OOPPs, consisting
of co-payments and deductible cash payments made by the patient/consumer to providers for a
particular medical treatment.  Thus, in our price index changes in supply price are indicative of
changes in the cost of treatment, while changes in the demand price can be traced both to changes
in the cost of treatment and changes in benefit design.  Our demand price concept relates to the
medical care component of the BLS’ Consumer Price Index (CPI).  As we discuss below, the
presence of insurance clouds the interpretation of the demand price index for depression as a CPI.
We also discuss important differences concerning the treatment of indirect consumer payments
via, for example employees’ contributions to employment-related health insurance.
To associate the notion of a price index for treatment episodes of care with official
price indexes published by the BLS, we now describe index number procedures currently
employed by the BLS, beginning with its PPI.
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II.A. BLS Procedures for Medical Care Related PPIs
The PPI “...measures average changes in selling prices received by domestic
producers for their output”, separately by industry.
2  The PPI takes as its definition of an industry
that based on the Standard Industrial Classification (SIC) code, using 4-digit SIC industries and
their aggregates.
3  Since its inception in 1902, the PPI has focused rather heavily on the goods-
producing sectors of the US economy.  In 1986, in recognition of the growing importance of
services, the BLS gradually began to broaden the PPIs scope of coverage in the services sectors,
including medical care.
Within each industry, the BLS calculates aggregate PPIs using a modified fixed
weight Laspeyres price index formula over individual price quotes, where fixed weights are based
on value of shipments data.  The primary price quote at the “cell index” level of disaggregation is6
“...the net revenue accruing to a specified producing establishment from a specified kind of buyer
for a specified product shipped under specified transactions terms on a specified day of the
month”.
4  Although the BLS seeks transactions rather than list prices for its price quotes, the
agency is well aware that compliance by firms is easier with list than with actual transactions
prices.  Participation by firms in the PPI is voluntary, with a “productive” compliance rate being
about 63% in 1992.
5
The BLS currently draws a sample of items for each industry on average about every
seven years, and then reprices this fixed set of items monthly until an entirely new sample is
drawn.  In 1995 the BLS announced that for certain industries, particularly technologically
dynamic ones such as pharmaceuticals and electronics in which seven year time lags could yield a
sample of products and services much older and quite unrepresentative of market transactions,
samples would be supplemented at one or two-year intervals.
For quite some time, the BLS has published PPIs for certain medical-related
manufacturing industries, such as pharmaceuticals and diagnostic equipment.  It is only recently,
however, that the BLS has begun publishing PPIs for medical service industries such as hospital
services and physician services.  The BLS initiated a PPI for an aggregate of health services in
December 1994, for offices and clinics of doctors of medicine in December 1993, and for
hospitals in aggregate and by type in December 1992.
A central measurement issue in the construction of medical price indexes involves the
specification and implementation of a concept of industry output.  For obvious reasons, the SIC
structure is not well-equipped to provide guidance to the BLS on what is the appropriate real
output concept in medical care industries, nor on how this output quantity and output price can
best be measured.
An alternative source for guidance on implementation of a medical care output
concept is provided by the Health Care Financing Administration (HCFA).  In 1983 HCFA
implemented a prospective payment schedule for inpatient hospital care whereby hospitals
received a fixed payment for each Medicare patient admission, regardless of the amount or7
duration of services actually provided the patient.  These Medicare prospective payment schedules
distinguish treatments by 24 major diagnostic categories, which are broken down further into 495
groupings of medical diagnoses and surgical procedures, known as diagnostic related groups
(DRGs).
6
DRGs provide one possible output concept, but currently DRGs only measure output
for inpatient hospital care; many outpatient commodities (e.g., prescription pharmaceuticals) and
services are not included in the DRG system.  Classification schemes used by health care payers
include version four of Current Procedural Terminology (CPT4) codes, a list containing
thousands of procedures for which physicians and hospitals can bill; these CPT4 codes can be
envisaged as inputs into the treatment of an illness or condition.
7  A systematic structure of
diagnostic codes for illnesses and conditions is version nine of the International Classification of
Diseases (ICD-9).
8  Relationships among ICD-9, CPT4 and DRG codes are multifaceted; a single
DRG encompasses treatment of somewhat arbitrary aggregations of distinct ICD-9 diagnoses,
alternative combinations of CPT4 codes can be used in the treatment of a particular ICD-9
diagnosis, and a given CPT4 procedure can be used in the treatment of various ICD-9 diagnoses.
The DRG system makes use of both ICD-9 and CPT4 coding systems.  Other diagnostic-related
systems used in setting risk-adjusted capitation rates include the Ambulatory Care Group
algorithm
9 and the Hierarchical Coexisting Conditions model.
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The BLS’ PPI program has initiated procedures for construction of medical service
PPIs at two rather aggregate levels, physician services and hospital services.  In turn these
encompass a variety of more detailed industries, such as physician services from psychiatrists,
general/family practitioners, internists, and hospital services from general medical and surgical
hospitals, psychiatric hospitals, and specialty non-psychiatric hospitals.
With respect to physician services, based on a sampling universe of all physician
practices in the US, the BLS constructs a sample frame of physician practice units.  From this
sample unit, the BLS randomly chooses a bill that measures the net price paid to the practice for
the entire set of services and procedures provided during an office visit, distinguished by payor8
type.  The physician’s output from this visit is represented by the content of the patient’s bill,
including CPT codes associated with that visit, and is related to a particular ICD-9 diagnosis.
Given this sample bill, the BLS contacts the physician practice unit each month and asks it to
reprice what the current net transactions prices would be for that particular fixed bundle/payor of
services.  Since the organization of physician practices has undergone considerable upheaval and
consolidation in the last few years, however, sample attrition in the BLS’ physician services PPI
has been considerable, and maintaining a sufficiently large response rate for repricing has proven
to be difficult.
11
The hospital services PPI measures net prices paid to hospitals for the entire bundle of
services received during a hospital stay associated with a particular ICD-9 diagnosis, given the
payor type.  Hospital output is represented by the content of a patient’s bill, including all room,
medical supplies, drugs and ancillary services provided the patient during a single hospital stay.
The sampling universe for the hospital services PPI is taken from the American
Hospital Association, stratified by hospital size, public vs. private ownership, and type of medical
specialty.  Once a hospital is identified as a sample unit, the BLS chooses a fixed subset of DRGs,
and each hospital is then asked on a monthly basis to report on net transactions prices of a single
representative patient bill (typically the last patient bill on file for that DRG).  Since the identical
treatment bundle is not always observed in subsequent months, BLS reporters construct
subsequent fictitious DRG bundle prices by repricing the identical inputs.
12
It is worth noting that with both the physicians’ services and hospital services PPIs,
BLS use of fixed itemized components for obtaining price quotes does not capture major input
substitution of treatment for a condition, such as the changing mix of psychotherapy and
psychotherapeutic drugs used for the treatment of acute phase depression.  Such a zero-
substitutability definition of physician and hospital output leads to the existence of a substitution
bias, but that bias is of course not confined to medical PPIs, for it pervades the entire fixed weight
Laspeyres price index computational procedures.
Finally, for our purposes it is also useful to note that the BLS publishes a PPI for9
prescription pharmaceuticals.  Although pricing the output of prescription pharmaceuticals
presents some particularly interesting issues involving treatment of generic drugs, and of quality
improvements in new products, those issues are beyond the scope of this paper.
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II.B BLS Procedures for Medical Care Related CPIs
According to the BLS, the CPI is “...a measure of the average change in the prices
paid by urban consumers for a fixed market basket of goods and services.”
14  Based on data from
its Consumer Expenditure Surveys (CEX), the BLS identifies and defines a fixed ‘market basket’
of goods, employing a classification system known as the item structure, which is updated
approximately every ten years.  In January 1998 the BLS introduced its most recent major item
structure and fixed weight revisions, based on the 1993-95 CEX; from January 1987 until January
1998, fixed weights had been based on the 1982-84 CEX.
In contrast to the BLS’ recently initiated medical PPI program, the medical CPI has
been published regularly since 1935.
15  Currently the BLS publishes a monthly aggregate medical
care CPI (MCPI), sub-indexes for medical care commodities and medical care services, as well as
for prescription drugs and medical supplies, nonprescription drugs and medical supplies,
physicians’ services, hospital and related services, and health insurance.  Each of these medical-
related CPIs is based on consumers’ out-of-pocket expenditures (OOPPs), and thereby excludes
all medical payments by governments, as well as employers’ contributions to employee health
insurance; only medical OOPPs plus that portion of third party insurance paid for out-of-pocket
by employees is included within the scope of the MCPI.  Thus, although national health spending
in 1996 constituted 13.6% of GDP, the total weight given medical care items in the CPI in 1997 is
only 5.4%.
16
Recently the medical CPI has introduced a number of changes, some of which are
similar to those implemented several years earlier in the PPI.  Until at least 1990, in most cases the
MCPI priced specific input items at list prices, e.g., “chargemaster” fees for x-rays, laboratory
tests, and physicians’ office visits, rather than at the average actual transaction price for treatment
of, say, a child’s forearm fracture to a managed care organization obtaining a hospital discount.
1710
Since 1993 the BLS has attempted to obtain hospital transaction rather than list prices, but
through 1996, efforts “...yielded slow progress to date.”
18  Beginning with the January 1998
major revisions, more aggressive efforts have been made to obtain actual hospital prices by payor,
but information is not yet available on the composition and nature of hospital quotes now being
obtained.  While DRG hospital quotes have been considered for use in the MCPI, the BLS is
instead contemplating pricing “package” treatments, consisting of “highly standardized and tightly
defined components and risk factors” for conditions such as appendectomies, tonsillectomies and
cataract surgery.
19  Details on how such treatment packages would be defined have not been
released.  Finally, while revisions involving hospital service components of the MCPI have been
announced, the BLS has not yet published comparable information on revisions to the physician
service components of the MCPI.
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II.C BLS Procedures for Pricing Medical Treatments: Comments
For some time now, health economists and government statisticians have pointed to
directions toward which the pricing of medical care services should move.  Here we briefly
summarize several of the directions suggested by this literature.  First, as early as 1962 Anne
Scitovsky proposed
“...an index which would show changes, not in the costs of such
items of medical care such as drugs, physicians’ visits, and hospital
rooms, but in the average costs of the complete treatment of
individual illnesses such as, for example, pneumonia, appendicitis,
or measles.”
21
In Scitovsky [1967], this treatment episode approach was implemented on an illustrative basis for
five medical conditions.  Discussions of shortcomings and biases inherent in the BLS’ MCPI
approach, and of the preference for the treatment episode approach to medical price
measurement, have appeared steadily since 1967; see, for example, the “Measuring Changes in the
Price of Medical Care” chapter in various editions of the well-known health economics textbook
by Paul Feldstein [1979, 1983, 1988], and in the Baxter Foundation Prize Address by Joseph
Newhouse [1989].
Second, experts agree, the measurement of changes in the price of medical services11
should incorporate major quality changes, such as those involving adjustments for improvements
in health care outcomes.  In 1992, for example, Paul Armknecht noted that
“A new dimension needs to be included in the pricing of medical
services that includes outcomes, so that if cancer treatment results
in improved survival rates, this is reflected in the index.”
22
The Boskin Commission final report went further, asserting that “...we strongly endorse a move in
the CPI away from the pricing of health care inputs to an attempt to price medical care
outcomes.”
23  Although incorporation of quality and outcomes changes into medical price indexes
presents some significant conceptual challenges
24 and implementation difficulties, it is clear that
failing to address these aspects is likely to result in price measures that are unreliable and
inaccurate.
Third, use of fixed weights over extended periods such as 10-12 years in constructing
sub- and aggregate price indexes is particularly inappropriate in the medical care sector, where
both institutional and technological changes are rapidly occurring.  Note that the frequency with
which fixed weights are updated is distinct from the issue of which index number formula (e.g.,
Laspeyres, Paasche, or Tornquist approximation to the Divisia) is preferable.  For the rapidly
changing medical care sector, decennial updates of fixed weights with old weights being fifteen
years out of date before the new revision occurs (i.e., use of 1982-84 CEX weights through
December 1997) results in price indexes whose accuracy and reliability can legitimately be called
into question.
In the research reported here, we extend previous research aimed at constructing
CPI- and PPI-like medical price indexes that deal with prices of treatment episodes rather than
prices of discrete inputs, that are based on transaction rather than list prices, that take quality
changes and expected outcomes into account, and that employ more current expenditure weights
in the aggregation computations.  Before describing the components of this research, however,
we digress to discuss the illness whose treatment price we measure, namely, acute phase major
depression.12
III.  THE NATURE AND PREVALENCE OF MAJOR DEPRESSION
Depression is commonly characterized by melancholy, diminished interest in pleasure
in all or most activities, sleep disorders, and feelings of worthlessness.  In order for a patient’s
condition to be considered as an episode of major depression, a clinician must determine that a
very specific set of clinical criteria have been met.  According to the Diagnostic and Statistical
Manual of the American Psychiatric Association (Fourth Edition, DSM IV), major depression is
diagnosed when the following is observed:
The presence of one of the first two symptoms, as well as at least
five of nine total symptoms.  The symptoms must be present most
of the day almost every day, for at least two weeks.  The symptoms
include:
1)  depressed mood most of the day nearly every day;
2)  markedly diminished interest or pleasure in almost all activities most of the day;
3)  significant weight loss/gain;
4)  insomnia/hypersomnia;
5)  psychomotor agitation/retardation;
6)  feelings of worthlessness (guilt);
7)  fatigue;
8)  impaired concentration (indecisiveness); and
9)  recurrent thoughts of death or suicide.
25
Two dimensions of depression involve its persistence.  A single episode of the illness
is self-explanatory given the above diagnostic criteria.  A recurrent depression is defined by two
or more major depressive episodes each separated by at least eight weeks of return to usual
functioning.
26  Episodes of illness come and go, last from several weeks to several months, and
are followed by periods of relatively normal mood and behavior.  Untreated, the average
depressive episode lasts from four to six months.  Although the vast majority of individuals who
experience an episode of major depression return to their original level of functioning, between 20
and 35% experience persistent symptoms; when these persistent symptoms last for 24 months or
longer, these cases are referred to as chronic depression.
27  Approximately 50% of all people
having a depressive episode can be expected to have a recurrence, usually within two or three
years.  Once an individual has a second episode, additional recurrence is 70% likely.
28  The13
lifetime average for depressive episodes is five to seven, but as many as forty episodes have been
reported.
29
A number of studies have shown that depression has similar or greater functional
impairments than those attributed to other episodic and chronic medical illnesses.
30  Episodes of
depression can be classified according to severity: mild, moderate or severe.  Mild depression
typically involves the minimum number of symptoms required to meet clinical criteria and minor
functional impairment.  Moderately severe episodes are characterized by an excess in symptoms
above the minimum to meet clinical criteria and by greater degrees of functional impairment.
Severe major depression involves a number of excess symptoms above the minimum and
significant degrees of functional impairment including the ability to work or conduct usual
activities.
Epidemiological research indicates that in the early 1990s, 10.3% of the U.S.
population met the criteria for major depression at some time during a 12 month period.
31
Depression is often accompanied by other forms of ill health, such as anxiety, eating disorders,
substance abuse or other medical conditions.
32  Although the reasons are still not well understood,
women -- particularly women under age 25 -- are much more likely to suffer from depression than
are men; the relative lifetime female/male prevalence rate is about 1.7.  Rates of recurrence and
chronicity for major depression appear to be no different for women and men.
33
IV.  ALTERNATIVE TREATMENTS FOR ACUTE PHASE MAJOR DEPRESSION
The acute phase of major depression is typically defined as the stabilization of most
acute symptoms.  In practice, standards of care typically identify the acute phase as occurring
over a 12-week period.  In this research we allow protocol levels of acute phase treatment to
occur over a 6-month period to recognize that actual practice departs from the controlled
environment of efficacy research.  In clinical practice, continuation therapy frequently follows on
acute phase treatment in hopes of preventing relapse.  If a recurrent episode of major depression
occurs, maintenance treatments are often initiated to prevent further recurrences [Kupfer, 1991].14
Given the information available in claims data, distinguishing between acute and
continuation phase treatment is difficult.  We employ acute phase standards of care to establish
expected outcomes, but in our empirical implementation we undoubtedly will mix acute and other
phases of care.  Clinical research on the continuation phase of treatment is less developed, and
definitive protocols have not been as widely adopted in many clinical settings.
A. Recent Developments in Psychotherapy and Antidepressant Medication
Treatments for acute phase major depression have advanced considerably during the
last two decades.  In the area of psychotherapy, a variety of new techniques has expanded
treatment options well beyond traditional psychodynamic or psychoanalytic approaches.
Interpersonal therapy (IPT), behavior therapy (BT), family therapy, and cognitive behavior
therapy (CBT) are each relatively new.  Evidence from controlled clinical trials suggests that
when applied as the single mode of treatment for less severe forms of acute phase major
depression, each of these therapies reduces depressive symptoms.  Moreover, relative to
antidepressant medication as the sole treatment, each has generally been shown to perform at
comparable levels of efficacy and to have similar outcomes.
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Extraordinary advances have been achieved in the last two decades in the area of
antidepressant medication.  Although very recent developments expand the therapy set even
further, over the 1991-95 period examined here three general classes of antidepressant
medications were employed.  These are: (i) cyclic antidepressants that include the widely used
tricyclic antidepressants (TCAs) and a number of lesser known drugs such as trazodone; (ii)
selective serotonin reuptake inhibitors (SSRIs) which include brand name drugs such as Prozac,
Zoloft, Paxil and Luvox;
35 and (iii) monoamine oxidase (MAO) inhibitors which, due to
considerable side effects and dangerous interactions, are generally used only for patients resistant
to other forms of treatment.
Newer SSRIs offer some distinct advantages over older TCAs, although in
randomized controlled trials, clinical efficacy rates are similar.  SSRIs are associated with lower
risk of overdose, and reduced levels and numbers of side-effects.  Important side effects15
frequently associated with TCAs include drowsiness, dry mouth, impaired ability to concentrate,
seizures and weight gain.
36  The side effects most prominently associated with use of SSRIs relate
to sexual dysfunction (particularly for males) and anxiety.  The advantages of SSRIs come at a
significantly higher pecuniary cost than most TCAs.
Psychotherapeutic interventions have frequently been combined with antidepressant
medication as a combination strategy for treating major depression.  The specific interventions
that have been most intensively studied are the use of TCAs in combination with either IPT, BT
or a general unspecified form of short-term psychotherapy.  To date, no clinical studies have been
reported in the literature which systematically assess the combination of the newer SSRIs and
psychotherapy.
37  It is generally presumed, however, that such combinations will be at least as
efficacious as the combination of TCAs and psychotherapy.
Finally, electroconvulsive therapy (EPT) is an effective treatment, but ECT is typically
limited to rather special circumstances when the patient’s depression is severe and is complicated
by a number of other psychiatric symptoms including psychosis, catatonic stupor, or high risk of
suicide.
In the analysis reported below, we focus on outpatient treatments for major
depression; these constitute the vast majority of treatment episodes (75 to 80%).  We do this for
several reasons.  First, inpatient claims data typically do not contain information on the drugs
prescribed for treatment; thus characterizations of inpatient care are inherently incomplete.
38
Second, because of other incomplete information regarding illness severity and comorbid
conditions, it is difficult to use administrative claims data to characterize fully an illness diagnosis,
and therefore to make judgments about the appropriate use of hospital services for treating major
depression.  Third, few clinical trials specifically address inpatient treatment for major depression,
making it difficult to assign outcomes to treatments.  Finally, because there was considerable
evidence of overuse of hospital services in the aggregate during the late 1980s and early 1990s,
the inclusion of hospital services in our 1991 base year could make interpretation of price changes
troublesome.
39  This strategy of limiting severity cases by excluding individuals hospitalized for16
treatment of depression is likely to be only partly successful.  During the 1990’s there has been a
substantial reduction in inpatient psychiatric admissions and in the length of stay for hospitalized
cases.  The implication of this is that the population of people treated only on an outpatient basis
may be getting sicker over time.
In our analysis, we therefore focus on the use of various antidepressant medications
alone, several forms of psychotherapy alone, and several drug-psychotherapy combination
treatments.  Because of very small sample sizes, we do not incorporate treatment involving ECT
or the MAO inhibitors.
B. Results From Comparative Efficacy Studies
We now provide a brief summary of research results comparing the efficacy of
alternative treatments for depression of varying severity.  We divide depression severity into two
classes: severe and less severe (hereafter, mild).  We have reviewed approximately 30 major
clinical trials and meta-analyses from the clinical literature on comparative efficacy of acute phase
treatments.
40  This literature points to several key conclusions.
First, psychotherapies of all kinds have been shown to result in superior outcomes
compared to no treatment.  When compared amongst themselves, the different forms of
psychotherapy appear to have no significant differences in outcomes.
41
Second, for less severe forms of depression, psychotherapies alone, TCAs with
medical management, and SSRIs with medical management appear to produce comparable
outcomes.  Each of these therapies produced significantly better outcomes than placebo
treatments.  Versions of these results have been reported in numerous large treatment trials and by
meta-analyses of smaller clinical trials.  Combination treatments with these as components also
generate equivalent levels of efficacy for less severe forms of depression.
Third, for more severe forms of depression, the bulk of the evidence suggests that
TCAs alone, SSRIs alone, and combinations of drugs and psychotherapy have comparable levels
of efficacy, and each results in superior outcomes compared to psychotherapy alone.  Recently
some evidence has emerged showing some extra improvement from the combination treatments17
relative to medication alone.
42  We believe it is premature to conclude that combination treatments
offer significantly higher levels of efficacy than do antidepressant medications alone (or with
medical management, as is typically the case).
Based on these observations from the literature, we view all the major treatment
technologies as offering comparable expected outcomes for the average care of less severe acute
phase depression.  For severe depression, we view TCAs and SSRIs alone as comparable to each
other and to combinations of TCAs and SSRIs with psychotherapy.
V.  IDENTIFYING COMPARABLE TREATMENT BUNDLES FROM CLAIMS DATA
The results from our review of the clinical trials literature enable us to develop a set
of treatment “bundles” that groups therapies into what we envisage as therapeutically similar
groups for treatment of a specific form of major depression.  This identification of treatment
bundles that result in similar expected health outcomes is a crucial step in the construction of
medical treatment price indexes that take expected outcomes into account.  The implicit
assumption we adopt here is that obtaining therapeutically similar outcomes from alternative
treatments provides a useful approximation to achieving similar expected utility levels.
43
A. The MEDSTAT Data
To identify empirically comparable treatment bundles for acute phase major
depression, we employ a dataset consisting of retrospective insurance claims from four large self-
insured employers that offered 25 health plans to 428,168 employees and their dependents for the
years 1991 through 1995.  The data were obtained from MEDSTAT Inc., and contain information
on prescription drug claims, inpatient hospital treatment, outpatient visits, ICD-9 diagnoses,
CPT4 procedures, and the demographic characteristics of all covered individuals.  The health
benefits offered to enrollees in this data base are quite generous relative to the general market for
private health insurance in the US.
During the five years observed, important changes occurred in the terms of insurance
coverage for mental health care.  While the vast majority of plans represent so-called managed18
indemnity plans (90%-94%), the management of mental health care benefits changed for a
substantial number of enrollees between 1991 and 1995.  Beginning on January 1, 1994, about
eight percent of enrollees had their mental health coverage “carved out” to a specialty mental
health managed care company.
44  In January 1995 an additional 35% of enrollees had their mental
health benefits carved out.
It is reasonable to expect that these carve-out arrangements affected both the input
prices and the quantities of specific delivered services, such as visits.
45  Changes in the extent of
carve-out arrangements might also have affected the general clinical strategies used in treating
major depression.  Recent analyses by Wells et al. [1996] and by Berndt, Frank and McGuire
[1997] show clear differences in treatment patterns between carve-out managed care plans and
treatment of mental health care financed by general health insurers, with carve-out arrangements
being associated with a higher likelihood of using prescription drug treatments.
Each outpatient and prescription drug claim can accommodate two ICD-9 diagnostic
codes.  In identifying cases of major depression, we used ICD-9 codes 296.2 (major depressive
disorder - single episode) and 296.3 (major depressive disorder - recurrent episode) to define
patients diagnosed with major depression.  We do this for three reasons.  First, the clinical trials
literature has for the most part employed these definitions in their entry criteria.  Second, chart
reviews have indicated that the specificity of these two diagnoses is high, i.e., the proportion of
true positives and false negatives is high, while the proportion of false positives is very low.
Third, clinicians could employ a more ambiguous diagnosis such as “depression not elsewhere
classified” or “neurotic depression”.  That clinicians designated their diagnosis as either 296.2 or
296.3 indicates a conscious act of volition.
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Using the diagnostic information and dates contained in the claims, we construct
episodes of treatment.  Since we do not directly observe symptoms in retrospective claims data,
we cannot make our claims-based definition of an episode of treatment correspond directly to an
episode of the illness.
47  When claims data indicate that psychotherapeutic drugs were prescribed,
we consider the number of days of treatment provided by the prescription as the time period over19
which an individual received care.  We follow American Psychiatric Association [1993] guidelines
in defining an episode of depression as new if a diagnosis is preceded by a period of at least eight
weeks of not meeting clinical criteria for depression.
48  Thus we use an eight week period without
treatment to define new treatment episodes.  In preliminary analyses, we experimented with
alternative definitions, such as those involving six or twelve week intervals; results were
essentially unaffected.  For treatments lasting longer than six months we count quantities of visits
and drugs meeting guideline standards for acute care occurring with the first six months of care
(e.g., 15 psychotherapy visits even if year totals were 25 visits).  To ensure that we consider the
full set of claims associated with the acute phase of treatment, we exclude episodes beginning in
the last six months of 1995, the last year in our sample.
When these criteria were applied to the MEDSTAT dataset, we defined 18,920
episodes of acute phase outpatient care over the 1991-95 time period.  Because we cannot fully
observe the treatment received for censored cases, we confine our attention to the 15,750
uncensored episodes in which we observe at least eight weeks without treatment before the
beginning of an episode; as noted above, 1548 episodes beginning in the last six months of 1995
were also excluded.  In order to limit the sample to less severe forms of depression, we eliminated
individuals with episodes involving inpatient hospital treatment for a mental illness any time
during the five years.  This reduced the number of episodes to 10,067.
Using information on procedures (e.g., type of visit, whether drug prescribed) as
given by the CPT4 codes, we can describe the composition of treatment that occurred within a
treatment episode.  Drug treatment is based on the national drug codes (NDC) reported on the
claim.  The NDC classification of antidepressant medications revealed use of seven TCAs, three
SSRIs, two other serotonin-related drugs
49, three MAO inhibitors, four anxiolytics and four
heterocyclics for treatment of depression.  In terms of composition, 54% of the drug claims
involved SSRIs, 19% TCAs, 19% anxiolytics and 7% heterocyclics.
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In previous research, we have reported that in the MEDSTAT claims data base, the
share of treatment accounted for by treatment involving psychotherapy claims appeared to20
increase  significantly in 1995, after having fallen steadily from 1991 to 1994.
51  Subsequent
research has indicated to us that while procedure codes are missing for many outpatient claims --
a common problem with claims data, the extent of missing claims in the MEDSTAT dataset is
particularly large in 1991 through 1994.  Thus, the apparent sudden increase in psychotherapy
claims in 1995 could simply reflect considerable missing claims from 1991 through 1994.
Hereafter we call the data underlying this previous research our “old” dataset.
To identify missing psychotherapy claims not explicitly delineated by CPT4 codes, for
our “new” dataset we have developed an algorithm in which a psychotherapy procedure code is
assigned to claims with missing CPT4 codes if two visits are within 14 days of each other, if they
have the same charge, and if a previously psychotherapy-identified claim in the episode has the
same charge.
52  Use of this algorithm contributed to an increase in the number of identified
episodes.
Our primary analysis of the claims data considers only “pure” or “strict guideline”
treatments.  That is, initially we will only consider episodes of care that adhere strictly with
treatment definitions as tested in the clinical trials literature.  In this way we can directly link the
“price” of an episode of a well-defined treatment to the price of other therapeutically similar
treatments.  However, we will also report results based on findings derived from episode
treatment definitions that relax this stringent guideline restriction, in which we include treatment
slightly below guideline criteria and those involving some continuation phase treatment.
In our strict guideline analyses we identify seven major classes of treatments that have
been proven effective in the treatment of depression: (i) psychotherapy alone, 6-15 visits -- “PT
alone”; (ii) short term TCA treatment alone or with medical management -- “TCA alone”; (iii)
short term SSRI treatment alone or with medical management, 31-180 days -- “SSRI alone”; (iv)
short term TCA treatment (31-180 days) with some psychotherapy -- “TCA+PT”; (v) short term
SSRI treatment (31-180 days) with some psychotherapy -- “SSRI+PT”; (vi) short-term combined
TCA/SSRI treatment, 31-180 days -- “TCA/SSRI”; and (vii) short term combined TCA/SSRI
treatment (31-180 days) with some psychotherapy -- “TCA/SSRI+PT”.  With the exception of21
psychotherapy alone, episodes with anxiolytics also being prescribed are combined into the
appropriate class defined above.  Use of seven major classes of treatments in this new dataset
represents an expansion from the five used in our previously published research.  Another
significant change in the new data was to include episodes that involved long-term treatments or
those extending beyond 20 visits or six months.  For those episodes we included the components
of care consistent with the acute phase bundles specified above and excluded spending on the
remainder of the “episode.”  Using this expanded definition of an episode, we are more likely to
include continuation treatment in the analysis.  This may be especially true in the later years as
new recommendations about continuation treatment diffused into practice.  Thus, the new dataset
may be “pricing” acute plus early continuation phase care in the later years.  This would tend to
bias an index upward.  Evidence for this is reflected by an upward trend in the average duration of
SSRI treatment during the five years (from 87 days in 1991 to 126 in 1995).  This change
contributed to a substantial increase in the number of cases used in the analyses.
The new dataset also improved the definition of censoring.  In the “old dataset” to
limit our analysis to episodes for which we had information on the entire episode, all cases which
included treatments in the last 8 weeks of 1995 were eliminated.  This means that more episodes
were eliminated form 1995 than any other year.  More severe episodes in need of longer term
treatment may therefore have been disproportionately dropped from previous analyses.  This may
have biased the price index downward.  We have now corrected that “late 95” censoring problem
limiting our analysis to the first 6 months of treatment.  As mentioned previously, to ensure we
consider all treatments in the first 6 months of the episode, we do not consider episodes begun in
the last half of 1995.
Finally, the new dataset allows drug switching if they are consistent with standards of
care in clinical trials.  Again, the change would tend to increase the severity and complexity of the
treated population.  Drug switching has been increasing over time as new pharmaceutical agents
have become available (SSRIs and SNRIs).
It is informative to compare episodes defined in our new dataset, with that from the22
old.  As seen in Table 1, the most obvious change is that the number and proportion of episodes
receiving guideline-compatible treatments increase very substantially, from 2348 to 5039, or, from
23% to 50%.  There are 2980 guideline compatible episodes in the new dataset that were not in
the old, and 289 in the old that do not appear in the new dataset.
There is also some evidence suggesting that in the new dataset, a greater number of
episodes are associated with other mental health comorbidities.  While new-old differences are
relatively small in terms of substance abuse comorbidities in guideline compatible episodes (2.5%
vs. 2.8%), 17.9% of acute phase depression episodes in the new dataset simultaneously involve
treatment of schizophrenia or bipolar depression, while in the old dataset this proportion was a
smaller 15.8%.  For the various panic and anxiety comorbidities, the new-old proportions are
3.3% vs. 2.9.  The literature, as well as our own discussions with clinician, suggest (1) that major
depression and bipolar illness are often mistaken for one another, and (2) treatment of depression
with comorbid psychoses and substance abuse is both common and difficult.
We interpret differences between the new and old datasets as therefore moving us
away from the more pristine world of clinical trials to a more realistic and more complicated
treatment environment in which mental illness comorbidities are more prevalent.
It is worth noting that differences between the new and old datasets in terms of other,
non-mental health comorbidities are rather minor.  As seen in the bottom panel of Table 1, for
example, the proportion having no such comorbidities is 48.2% in the new dataset, and 48.3% in
the old; relative to the old dataset, the proportion having one other medical comorbidity is slightly
higher (37.9% vs. 36.2%), but is slightly lower for two or more comorbidities (13.9% vs. 15.6%).23
Table 1
COMPARISON OF DATASETS BASED ON NEW AND OLD EPISODE DEFINITIONS
New Data Old Data In New but
Not in Old
Data
In Old but Not
in New Data
Total Episodes 10,067 10,368
Episodes Guideline Compatible 5,039 2,348 2,980 289
Mental Health Comorbidities*
Substance Abuse 2.5% 2.8% 2.6% 4.2%
Schizophrenia / Bipolar 17.9% 15.8% 20.1% 23.2%
Anxiety / Panic 3.3% 2.9% 3.9% 6.2%
Sum of Other Medical Comorbidities**
0 48.2% 48.3% 47.5% 41.5%
1 37.9% 36.2% 39.3% 38.8%
‡ 2 13.9% 15.6% 13.2% 19.7%
* Panic/anxiety diagnoses are ICD-9 300, 300.1-300.4; schizophrenia/bipolar are all 295s, 296.0-
296.1, 296.4-296.8; other includes obsessive/compulsive disorders (300.3), bulimia (783.6),
depression not otherwise specified (311) and dysthymia (300.4).
** Other medical comorbidities are sense organs, circulatory system, cerebrovascular, digestive
system, kidneys, prostate, pregnancy, and nervous system.
B. On Guideline Compatibility
Earlier we noted that of the 10,067 episodes identified in the new dataset from 1991
through 1995, 5039 (50%) were guideline-compatible.  It is interesting to note that in our new
dataset the proportion of episodes receiving guideline-compatible treatment rose from 35% in
1991 to 42% in 1992, then increased sharply in 1993 to 56%, and remained at 56% in 1994 and
1995.
The interpretation of guideline-incompatible treatments is difficult with claims data.
For example, 1308 episodes (33% of the 3965) treated with psychotherapy alone consisted of a
single visit.  In addition, 1672 or 16% of all episodes received neither psychotherapy nor an
antidepressant drug.  Such single visits might have taken place for the purpose of “ruling out”24
major depression as the relevant condition to be treated in favor of a somatic condition or another
mental disorder.  In such cases, the visit should not be viewed as “inappropriate treatment” but
rather as an appropriate assessment, consistent with the Depression Guideline Panel statement
[1993, p. 36]:
“Effective treatment rests on accurate diagnosis.  The practitioner
must first determine whether the patietn has a clinical depression or
is simply suffering normal sadness or distress...For patients who
have  very mild cases of major depression or whose diagnosis is
unclear and who are not in immediate danger or are not suffering
significant functional impairment, the practitioner may want to
schedule one or two additional weekly evaluation visits to
determine whether symptoms will abate without formal
treatment...”
The implication of this is that with retrospective claims data, distinguishing treatment and
assessment is quite uncertain.  Hence we are somewhat unclear as to whether only 50-60% of
care lies on the production frontier, or whether another 10-20% of treatments were dealt with
properly but did not require treatment of the type studied here.  It is important to note here that
our use of guideline standards of care imposes a rather unrealistic shape to the production
function for treatment of depression.  It takes on a step function form.  For example, if one were
to receive 6 psychotherapy visits for treatment of depression, our analysis would treat the case as
“effective” whereas 4 or 5 visits would be viewed as “ineffective.”  This is unlikely to be an
accurate representation of clinical reality.  Nevertheless, there is little systematic analysis upon
which to make alternative assumptions.  Thus, we use the step function production model as a
point of departure.
With these difficulties in appropriate interpretation as a caveat, we now examine in
greater detail the extent of guideline compatibility in the various treatment bundles of the new
dataset.
Of the 10,067 episodes, 3765 were treated with psychotherapy alone, and 376 with
psychotherapy and anxiolytics.  Within the claims data, no distinction was made between different
types of psychotherapy.  Considering the 3044 treatments involving 50 minute psychotherapy25
sessions, we find that 1658 received four or fewer visits, and 800 only a single visit.  Of the 921
episodes involving 20 minute psychotherapy alone, 508 involved just one brief visit, while 178
episodes were treated with between two and five brief sessions.  An additional 20 episodes
involved some form of group therapy treatment, with only 25% of those having more than three
visits.
While clinical trials data indicate that individuals show partial response to
psychotherapy with six weeks of treatment (with weekly sessions) and remission in twelve weeks,
published guidelines for the treatment of acute phase depression do not indicate any demonstrated
effectiveness for fewer than six visits.  The benefits of short psychotherapy visits, in the absence
of antidepressant medication, have not been studied and therefore cannot be considered either
effective or ineffective treatment.  Although clinical trials and published treatment guidelines
indicate psychotherapeutic treatment alone is an effective treatment, in our data, of the 3044
episodes given this treatment, only 1386 episodes (46%) can be considered to have completed a
psychotherapy regimen that is consistent with guideline treatments.
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Turning attention now to treatments involving antidepressant medications, we begin
by noting that claims data do not include information on how many days’ medication was actually
taken; as a proxy, we use the number of days of treatment for which a prescription was filled.
Of the 10,067 episodes considered, 231 were treated with TCA either alone (176) or
in combination with anxiolytic medication (55).  Of these 231 episodes, 55 (24%) were treated
with less than 30 days of medication and 29 with ten or fewer days.  Generally, the clinical
literature (and the APA guidelines) indicate that while patients may show some improvement to
antidepressant medication by the end of the first week, full response to acute phase depression
may take four to six weeks.
An additional 741 episodes were treated with SSRIs either alone (604) or in
combination with anxiolytic medication (137); 77 (10%) of these episodes were treated with
fewer than 30 days of medication.  Because individuals have differing reactions to drugs, some
individuals are appropriately treated with one class of antidepressants, and then switched to26
another class.  In our sample, 95 episodes were treated with both TCAs and SSRIs, but 20 of
these episodes had less than 30 days of both drugs.
Several episodes were treated with medications other than SSRIs and TCAs.  In our
sample ten episodes were treated with MAO inhibitors, while 164 were treated with heterocyclics.
An additional 124 episodes were treated with anti-anxiety medication alone, a protocol which has
not been approved by the FDA for the treatment of major depression.  The use of anti-anxiety
medication in the treatment of depression remains controversial.  The use of alprazolam may be
appropriate, if other medication is contraindicated.  There is no clinical trial evidence for the
efficacious use of other anxiolytic medications.
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Finally, in terms of combination treatments, the share of episodes treated with
psychotherapy and antidepressant medication grew over time.  Over the entire five year time
period, 552 treatment episodes involved both some TCA and some psychotherapy, while 2169
included both SSRI and some psychotherapy.  A large share (36%) of the episodes treated with
combination treatments had three or fewer psychotherapy visits, and an additional 382 episodes
were treated with some TCA, some SSRI and some psychotherapy.
C. Comparison With Results From Other Studies
The patterns of care observed in this dataset raise issues related to the likely
effectiveness of treatment, given the substantial proportion of episodes involving guideline-
incompatible treatments.  One potential criticism of the patterns of treatment bundle data
presented above is that it is based on retrospective claims data.  Claims data are useful in that the
retrospective medical treatment of many individuals can be analyzed efficiently and at minimal
expense.  In addition, such observational data reveal the “real world” practice of medicine, not the
pristine clinical trial environment.  Claims data are also used for quality assessment by
organizations constructing “report cards” on health care organizations.  Yet claims data has been
fairly criticized for several reasons.  The accuracy of diagnoses and recorded data are sometimes
questioned, and omissions in records are common.  For example, depression has been shown to be
under-diagnosed by primary care physicians and over-diagnosed by psychiatric clinicians.
5527
Other studies have found treatment patterns for depression that are generally
consistent with the patterns we observe here.  The Medical Outcomes Study (MOS) consisted of
635 individuals diagnosed with depression or with current depressive symptoms for whom data
was collected by self-administered questionnaires, patient diaries, phone interviews and health
examinations.  The MOS found that only 23% of depressed patients had used an antidepressant
medication in the prior month or used it daily for a month or more in the prior six months.  Of
those patients using an antidepressant medication, 39% used an inappropriately low dose.
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The MOS did not report number of psychotherapy visits.  Instead it reported
‘counseling’, defining it as three or more minutes of counseling during the screening interview.
This makes comparison with published standards of care difficult.  Although 90% of patients of
mental health specialists were counseled, among general medical practitioners where most study
participants were treated, only 20% of managed care and 40% of fee-for-service patients were
counseled.
Another study of 88 outpatients enrolled in the NIMH Clinical Research
Collaborative Program on the Psychobiology of Depression found that prior to entry into the
study, only 19% of patients received an adequate dose and duration of antidepressant medication,
while 24% received some anti-anxiety medication.  Regarding psychotherapy visits, 44% were
seen for at least one hour weekly.
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Thus, the substantial proportion of patients in the MOS and NIMH studies apparently
not obtaining efficacious treatments, while perhaps surprising, is consistent with the treatment
patterns found in the claims data we observe here.
For our purposes of constructing price indexes for the treatment of acute phase major
depression, we must decide whether to utilize the data suggestive of treatment not consistent with
FDA approvals and AHCPR guidelines.  Since the interpretation of such treatments is
problematic, in our “strict guideline” analysis we confine our attention to episodes of treatment
defined as being consistent with AHCPR guidelines; however, in a separate analysis we also
include treatment bundles that are “close” to guideline standards.  Additional research on28
guideline-incompatible care and the shape of the production function for treatment of depression
is currently underway.
VI.  QUANTITIES AND PRICES OF ALTERNATIVE TREATMENT BUNDLES
We begin our empirical analysis by characterizing quantities and prices of the seven
treatment bundles.  In Table 2 we report guideline-compatible treatment quantities, by year.
Censoring at the beginning and end of our time span implies that in 1991 and in 1995, about 1500
episodes are identified, whereas in 1992-1994 the number is considerably larger at about 2400 per
year.  The two most common treatment bundles are SSRI+PT and PT alone.  Because of varying
sample size by year, quantity trends are more easily discerned by examining quantity proportions
rather than absolute levels; guideline-compatible treatment bundle quantity proportions are
reported in Table 3.
Table 2
GUIDELINE-COMPATIBLE TREATMENT BUNDLE QUANTITIES, BY YEAR
Treatment 1991 1992 1993 1994 1995 Total
PT Alone 214 311 321 311 229 1386
TCA Alone 32 45 43 37 19 176
SSRI Alone 52 113 188 205 110 668
TCA+PT 63 111 129 73 33 409
SSRI+PT 125 292 528 644 400 1989
TCA/SSRI 9 14 23 23 6 75
TCA/SSRI+PT 27 53 121 98 37 336
Sum 522 939 1353 1391 834 5039
Total Episodes 1479 2211 2426 2468 1483 10067
Percent Guideline-Compatible 35.3% 42.5% 55.8% 56.4% 56.4% 50.1%
A number of notable trends appear in Table 3.  First, there has been a very substantial
decline in PT alone treatments, from 41% in 1991 to 22% in 1994, and then up slightly to nearly
28% in 1995.  Second, for the medication only treatments, SSRI alone has grown from 10 to
13%, even as TCA alone declined from six to two percent; the sum of the two medication only29
treatments has remained relatively constant at 15-16%.  Third, most of the compositional change
among treatment bundles has involved the medication-psychotherapy combination treatments.
While the TCA+PT combination fell from 12 to 4% between 1991 and 1995, the SSRI+PT
treatment share doubled, from 24 to 48% of all treatments.  By 1995, the SSRI+PT combination
had become the modal treatment bundle.
Table 3
GUIDELINE-COMPATIBLE TREATMENT BUNDLE QUANTITY
PROPORTIONS, BY YEAR
Treatment 1991 1992 1993 1994 1995 Total
PT Alone 0.409 0.331 0.237 0.224 0.275 0.275
TCA Alone 0.061 0.048 0.032 0.027 0.023 0.035
SSRI Alone 0.100 0.120 0.139 0.147 0.132 0.133
TCA+PT 0.121 0.118 0.095 0.052 0.040 0.081
SSRI+PT 0.239 0.311 0.390 0.463 0.480 0.395
TCA/SSRI 0.017 0.015 0.017 0.017 0.001 0.015
TCA/SSRI+PT 0.052 0.056 0.089 0.070 0.044 0.067
In Table 4 we report the average supply price for each treatment bundle, by year;
recall that this supply price captures the sum of payments from insurers and patients/consumers to
providers.  As is seen there, annual price movements represent a mix of increases and decreases.
Between 1993 and 1994, for example, the price of one bundle increases and that of all other six
bundles decreases, while for 1994-95, price movements are reversed -- six up, and one down.  Of
particular interest is the extent to which compositional changes in quantities of treatment bundles
appear to be negatively related to changes in relative prices.  When entries in Tables 3 and 4 are
considered together, it becomes clear that compositional quantity changes do not follow simple
conceptions of downward sloping demand curves where quantity and “price” changes are clearly
negatively related.  From 1991 to 1992, for example, even as the supply price of SSRI alone more
than doubled from $52 to $113, the SSRI alone share increased from four to six percent;
similarly, the cost of the SSRI+PT combination bundle increased by about 150% from $125 to30
$292 between 1991 and 1992, yet the quantity share grew from 24% to 31%.  It is important to
note that the quality of treatment bundles may vary (e.g., side-effects).  Also, insurance coverage
drives a wedge between the supply and demand prices.  Both of these may help explain observed
patterns and they are discussed below.
Table 4
AVERAGE SUPPLY PRICE OF TREATMENT BUNDLE, IN DOLLARS BY YEAR
Treatment 1991 1992 1993 1994 1995 Average**
PT Alone $876 $853 $866 $818 $819 $846
TCA Alone 236 310 318 204 226* 267
SSRI Alone 311 387 309 308 344 328
TCA+PT 932 882 745 706 941 820
SSRI+PT 941 983 949 958 972 961
TCA/SSRI 649* 361* 449 423 328* 439
TCA/SSRI+PT 1002 1021 1062 953 977 1010
AVERAGE** 805 817 802 788 825
Notes: *  denotes a cell with less than 20 observations
** denotes a weighted average
This positive relationship between changes in supply price and quantity share is
observed in other years as well.  From 1992 to 1993, for example, the supply price of TCA+PT
fell by about 18% from $882 to $745, but its quantity share also dropped from 12% to 10%.
Between 1993 and 1994, while the cost of PT alone fell about 5% from $866 to $818, the PT
quantity share fell from 26% to 23%.  Similarly, for both TCA alone and TCA+PT, between 1993
and 1994 both prices and quantity shares fell.
What these quantity and supply price data suggest, therefore, is that factors other than
supply price are likely to have induced compositional changes among treatment bundles for acute
phase major depression.  Prominent among these, we conjecture, is the increased knowledge and
experience gained by physicians on the efficacy and effectiveness of the SSRI medications,31
particularly in combination with a limited amount of psychotherapy and changing insurance
arrangements.
Although compositional changes among treatment bundles may reflect a host of price
and non-price influences, it is clear that the dollar expenditure shares among the seven treatment
bundles have been greatly affected between 1991 and 1995.  These dramatic changes are evident
in Table 5.  While the expenditure share going to PT alone fell from 45% to 27% between 1991
and 1995, by 1995 the SSRI+PT bundle was responsible for more than half (56%) of all dollar
expenditures, up from 28% in 1991.  In 1991 the three singleton bundles of PT alone, TCA alone
and SSRI alone accounted for 50% of all treatment dollars in 1991, but by 1995 they only
captured 33% of expenditures.
Table 5
TOTAL EXPENDITURE SHARES BY TREATMENT BUNDLE, BY YEAR
Treatment 1991 1992 1993 1994 1995 Average
PT Alone 0.446 0.346 0.256 0.232 0.273 0.310
TCA Alone 0.018 0.018 0.013 0.007 0.006* 0.012
SSRI Alone 0.038 0.057 0.054 0.058 0.055 0.052
TCA+PT 0.140 0.128 0.089 0.047 0.045 0.090
SSRI+PT 0.280 0.374 0.461 0.563 0.565 0.449
TCA/SSRI 0.014* 0.007* 0.010 0.009 0.003* 0.008
TCA/SSRI+PT 0.064 0.071 0.118 0.085 0.053 0.078
Note:  * denotes a cell with less than 20 observations
Together, the patterns observed in Tables 2 through 5 suggest to us that rather than
PT and the SSRIs being viewed as simple singleton substitutes in the production of treatments for
acute phase depression, they are more accurately envisaged as being complementary in the sense
that the PT+SSRI combination has now become the modal treatment.
To this point, our discussion of treatment bundle price has focussed on the supply
price -- the sum of payments received from insurers and patients/consumers.  The demand price32
notion reflects the fact that patients receiving treatment for acute phase depression provide direct
payments in the form of copayments and deductibles.  In Table 6 we report average demand
prices for each of the seven treatment bundles, annually.  Trends in the demand price differ quite
markedly from those of the supply price.
Recall from Table 4 that the average supply price across all bundles fell slightly from
$805 in 1991 to $788 in 1994, and then increased to $825 in 1995.  In contrast, as seen in Table
6, from 1991 to 1994 the average demand price increased from $100 to $105, and then it
increased very sharply to $128 in 1995.  This sharp increase of 22% between 1994 and 1995 in
the average demand price across all treatment bundles reflects corresponding jumps in the PT
alone bundle (26%), SSRI alone (19%), SSRI+PT (17%), and TCA/SSRI+PT (21%).
Two main factors may account for changes in demand prices that differ so starkly
from supply price changes.  First are the changes in cost sharing provisions.  These are
documented in the MEDSTAT datset.  The MEDSTAT data indicated to us that in 1995, for a
number of insurance plans, benefit changes were introduced that increased substantially the
copayments and deductibles required of plan enrollees.
58  Second is the tendency to use out of
network providers in the context of managed care.  Coverage of care provided by non-network
providers typically carries higher copayments than does care received from a network clinician.
During the time period observed, networks were becoming more restrictive and behavioral health
carve-outs were introduced, which may have increased the share of care provided by non-network
providers.  The impact of these benefit design changes can be seen by computing the portion of
the total treatment cost borne directly by the patient, i.e., computing the ratio of the demand price
in Table 6 to the corresponding supply price in Table 4; we call this the OOPPs ratio.33
Table 6
AVERAGE DEMAND PRICE OF TREATMENT BUNDLE,
IN DOLLARS BY YEAR
Treatment 1991 1992 1993 1994 1995 Average**
PT Alone 121 122 122 123 155 128
TCA Alone 39 46 46 48 51 46
SSRI Alone 23 30 24 27 32 27
TCA+PT 128 124 116 113 117 120
SSRI+PT 102 105 115 121 142 120
TCA/SSRI 43* 47* 46 51 21* 45
TCA/SSRI+PT 102 121 131 135 163 132
AVERAGE** 100 101 102 105 128
Note: * denotes a cell with less than 20 observations
** denotes a weighted average
For the SSRI alone bundle, the OOPPs ratio increased only marginally, from 7% in
1991 to 9% in 1995.  For the very low total cost TCA alone bundle, the OOPPs ratio increased
more markedly, from 16% in 1991 to 23% in 1995; in absolute terms, this additional burden borne
by the patient was only $12 (from $39 to $51).  For the combination treatments involving PT and
the SSRIs, however, the increase was much more substantial, both in terms of OOPPs ratio and
absolute dollar burden.  In the SSRI+PT bundle, for example, the OOPPs ratio rose from 11% to
15% between 1991 and 1995, with the demand price increasing $40 from $102 to $142; even
more dramatically, for the TCA/SSRI+PT bundle the OOPPs ratio rose from 10% to 17%, while
the demand price jumped $61 from $102 in 1991 to $163 in 1995.  The changes resulted from
increased cost sharing for psychotherapy.
One important implication of these findings is that when considering construction of
price indexes for the treatment of a medical condition such as depression, it is imperative that
demand prices be distinguished from supply prices, for changes in insurance plan design benefits34
over time can introduce sharp differences into their time trends.
VII.  AGGREGATE PRICE INDEXES FOR THE TREATMENT OF DEPRESSION
With the prices and quantities of the seven treatment bundles as elementary building
blocks, we now move on to the construction of aggregate supply and aggregate demand price
indexes.  A variety of price indexes can be computed, each having implicit assumptions on the
extent of ex ante substitutability among the seven bundles.  Since we have discussed these
alternative index number formulae and underlying assumptions elsewhere
59, and since they are
well-known in the literature on index numbers
60, we provide only a very brief discussion here.
Fixed quantity weight indexes such as the Laspeyres and the Paasche reflect an
assumption of zero ex ante substitutability among the seven treatment bundles; the Laspeyres
employs a base period fixed weight, the Paasche the final period fixed weight.  The Cobb-Douglas
employs a fixed expenditure weight (here, equal to the mean expenditure share for each bundle
over time), and assumes the elasticity of substitution among treatment bundles equals unity for all
pairs of bundles.  When demand curves are downward sloping and bundle prices are all increasing,
between any two adjacent time periods the Laspeyres price index is greater than the Paasche.
In general the chained, or sequentially updated price indexes are viewed as being
preferable to the fixed weight indexes.  The Tornquist discrete approximation to the Divisia, and
the Fisher Ideal, make no a priori assumptions on the extent of substitutability among treatment
bundles.  The Tornquist weights percentage changes in each of the treatment bundles by the
arithmetic mean of the expenditure share in the two time periods, whereas the Fisher Ideal is the
geometric mean of the corresponding Laspeyres and Paasche indexes.  A commonly observed
empirical pattern is that the Tornquist and Fisher Ideal price indexes are very close to one
another, and both tend to be in between the Laspeyres and Paasche price indexes.
With this as background, we now report results of various aggregate price index
calculations, first in Table 7 as viewed from the supply price (i.e., PPI) vantage, and then in Table
8 from the demand side (i.e., CPI).35
The most striking result that immediately emerges from Table 7 is that, regardless of
which index number procedure is employed, over the 1991-95 time period the treatment price
index for acute phase major depression has hardly changed, remaining at 1.00 or falling slightly to
around 0.97.  Each of the price indexes reveal an increase from 1991 to 1992, they all fall in 1993,
all fall again in 1994 (to between 0.95 and 0.97), and then all increase in 1995.  Given some of the
data problems in 1995, this last finding should be viewed cautiously.  Differences among the
various fixed and chained indexes are relatively minor.
Table 7
ALTERNATIVE AGGREGATE PRODUCER (“SUPPLY”) PRICE INDEXES
FOR THE TREATMENT OF ACUTE PHASE MAJOR DEPRESSION
Price Index 1991 1992 1993 1994 1995
Fixed Weights:
Laspeyres 1.000 1.003 0.975 0.931 0.976
Paasche 1.000 1.027 0.996 0.974 1.000
Cobb-Douglas 1.000 1.018 0.985 0.953 0.992
Chained Weights:
Laspeyres 1.000 1.003 0.969 0.938 0.968
Paasche 1.000 1.011 0.976 0.952 0.978
Fisher Ideal 1.000 1.007 0.97 0.945 0.973
Tornquist 1.000 1.007 0.972 0.945 0.972
BLS PPIs*
Aggregate PPI 1.000 1.012 1.025 1.031 1.051
Health Services 1.000 1.024
Antidepressants 1.000 1.076 1.134 1.162 1.204
Psychiatric Hospitals 1.000 1.024 1.060 109.9
* BLS indexes normalized to appropriate base year
By comparison, in the bottom panel of Table 7 we report various PPIs published by
the BLS.  Over the 1991-95 time period, the aggregate PPI for all finished goods increased about
5%, and that for antidepressant prescription drugs increased by about 20%.  From 1992 to 1995,
the PPI for psychiatric hospital services increased by about 10%, while between 1994 and 199536
the overall health services PPI increased 2.4%.  Thus, while our various supply price indexes for
the treatment of acute phase depression are either flat or very slightly falling, they all grow
considerably less than the various official PPIs, i.e., the “real”, inflation adjusted price index for
the treatment of acute phase depression has fallen over the 1991-95 time span.
Table 8
ALTERNATIVE AGGREGATE CONSUMER (“DEMAND”) PRICE INDEXES
FOR THE TREATMENT OF ACUTE PHASE MAJOR DEPRESSION
Price Index 1991 1992 1993 1994 1995
Fixed Weights:
Laspeyres 1.000 1.028 1.041 1.063 1.266
Paasche 1.000 1.037 1.080 1.118 1.334
Cobb-Douglas 1.000 1.037 1.069 1.110 1.300
Chained Weights:
Laspeyres 1.000 1.028 1.048 1.081 1.281
Paasche 1.000 1.032 1.065 1.104 1.317
Fisher Ideal 1.000 1.030 1.056 1.092 1.299
Tornquist 1.000 1.030 1.057 1.093 1.298
BLS CPIs*
All Items 1.000 1.030 1.061 1.088 1.119
Medical Care 1.000 1.075 1.146 1.205 1.266
Prescription Drugs 1.000 1.075 1.117 1.155 1.177
* BLS indexes normalized to 1991 base year
Index number afficionados might notice, however, that the typically observed
inequality relationships among the Laspeyres and Paasche price indexes are not present here.  For
example, for both fixed and chained weight versions, the Paasche price index is larger than the
Laspeyres.  The reason this occurs is that, as noted in Section VI above, in a number of cases
changes in treatment bundle supply prices and quantity shares are positively rather than negatively
correlated.  Because the price index calculations do not take into account factors affecting
demand other than price, and because consumers do not face supply prices, there is the
appearance of a positive relation between quantity and supply price.  We discuss other price-37
related issues in Section VII below, where we deal with hedonic price indexes.  Finally, note that
as is usually the case, the Fisher Ideal and Tornquist indexes are always in between the chained
Paasche and Laspeyres indexes.
We now turn to a discussion of aggregate price indexes viewed from the demand side,
i.e., the patient/consumers’ OOPPs expenditures.  As seen in Table 8, the demand aggregate price
indexes have very different time trends than do the supply aggregate price indexes.  Each of the
price indexes exhibits an increase between each pair of adjacent years, with the 1994-95 price
increase being particularly dramatic.  By 1995, the fixed weight price indexes (normalized to
1.000 in 1991) ranged between 1.27 and 1.33, while the chained indexes had a slightly smaller
variation, between 1.28 and 1.32.  Between 1991 and 1994, the price indexes increased by only
about 10%, but in 1995 the increase was much larger, averaging around 20%.  As discussed in
Section VI, we attribute this sharp increase to benefit design changes in 1995 that increased
patient copayments and deductibles.
The discrepancy between the PPI and CPI results highlight several important points in
interpretation of the data.  First is that if the elasticity with respect to the demand price is less than
unity (in absolute value), spending must increase.  Since cost sharing increased notably and
demand estimates suggest an elasticity of less than unity, it is not surprising that the CPI increases
over time.  Second, and more important, is the welfare interpretation of these changes.  It is well
known that low levels of demand side cost sharing in medical insurance is associated with welfare
losses due to moral hazard [Newhouse, 1993].  Thus, changes in the CPI for depression may
reflect reduced moral hazard in addition to higher prices per unit of “effective care.”  Research by
Manning and Marquis [1993] suggests that 50% cost sharing for mental health care was optimal
in a fee-for-service context.  Because observed rates in our data are quite a bit lower, gains from
reduced moral hazard may be significant.  Because interpretation of the CPI is unclear, we focus
more attention on the PPI.
VII.  HEDONIC PRICE INDEXES38
An enduring issue in price index measurement is how one should make adjustments
for quality change.  Quality adjustments could be significant here, for it is reasonable to expect
that the characteristics and attributes of the acute phase of treatment for depression has changed
over time, and that changes in the underlying patient population might also have occurred.
Although its use to date in the medical marketplace has been limited, the hedonic
price approach has been used in many other contexts to adjust price movements for (not fully
priced) quality changes.
61  We now briefly outline our implementation of hedonic price
measurement for the treatment of acute phase depression.
We expect that treatment costs for depression are affected by patient characteristics,
various attributes of antidepressant medications, the type of treatment given the patient, and the
year in which the treatment episode began.
Patient characteristics for which we have data include the patient’s gender, age,
general medical condition (measured by the number of comorbid general medical conditions, as
noted on the bottom of Table 1), the industry in which the plan enrollee is employed
(transportation, communication, utilities; services; or government), and information on the
patient’s mental health comorbidities.  With respect to these mental health comorbidities, we
construct dummy variables for whether the patient is also diagnosed with a substance abuse
disorder, a panic/anxiety disorder, schizophrenia or bipolar depression, depression not otherwise
specified, and whether the current episode involves a recurrence of major depression.
For attributes of the various antidepressant medications, we employ data on the half-
life of the medication, and on the number of side effects that frequently accompany use of the
medication.
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Regarding treatments, we create dummy variables for each of the seven guideline-
compatible treatment bundles described earlier.  We also create a dummy variable indicating
whether at the start of the episode the individual was enrolled in a behavioral health carve-out.
Finally, we create dummy variables indicating the year in which the treatment episode began.
The dependent variables in the hedonic regressions are the natural logarithm of the39
supply price and of the demand price.  The explanatory variables are the patient, medication,
treatment and time variables discussed above.  The set of omitted dummy variables, and thus the
reference case, is that for a female; where the enrollee is employed in the transportation,
communication or utilities industry; has none of the mental health comorbidities noted above; is
not being treated for a recurrent episode of acute phase depression; treatment consists of PT
alone; and the treatment episode began in 1991.  Parameter estimates for the supply price
equation are in the left panel of Table 9, while estimates for demand price equation are in the right
panel.  A number of results are worth mentioning in detail.  We begin with the supply price.
First, characteristics of the patient and their illness have a statistically significant
impact on treatment costs.  While age does not appear to affect the supply price, mental health
comorbidities such as anxiety/panic, schizophrenia/bipolar depression, and depression not
otherwise specified all have a positive and significant impact.  Somewhat surprisingly, comorbid
substance abuse has a negative coefficient estimate, although not significant.  The sum of the
patient’s other general medical comorbidities is also negative, but not significant.  Finally,
treatment costs for patients in which the enrollee is employed in the services or government
sectors are considerably lower than if the industry involves transportation, communications and/or
utilities.
Second, attributes of the antidepressant medications also affect supply prices of
treatment, even when one controls for type of treatment.  Specifically, within the various bundles
involving prescription drugs, greater side effects are associated with lower supply prices (lower
side effects with higher supply prices), and increased half-life of the drug (mitigating the negative
impacts of occasional forgetting to take the medication) also raises the supply price.  Relative to
PT alone, treatment with TCA alone or SSRI alone reduces the supply price significantly, while
use of SSRI+PT or TCA/SSRI+PT increases supply price.40
Table 9
PARAMETER ESTIMATES FROM HEDONIC PRICE REGRESSIONS
(Absolute value of t-statistic in parentheses, from robust standard error)

















































































































































































2 0.328 0.088 0.277 0.083
RMSE 0.689 0.802 1.168 1.315
N 5034 5034 5034 5034
Somewhat surprisingly, we find that whether at the beginning of the treatment
episode the patient was enrolled in a mental health carve-out has no significant impact on supply
price.  To check whether the carve-out impact was diluted because of differential treatment
bundles used by the carve-out, we also estimated a supply price equation in which the treatment
bundle dummy variables were deleted; results are given in the second column of parameter
estimates in Table 9.  Although the goodness of fit was reduced considerably when the treatment
bundle variables were deleted, the carve-out parameter estimate remained insignificant.  This may
be due in part to the fact that the comparison conditions involved managed indemnity
arrangements which tend to negotiate price discounts and shift care patterns.
Of particular interest are the parameter estimates on the 1992-95 yearly dummy
variables.  In the context of the hedonic price equation, these parameter estimates indicate how
the supply price changed relative to 1991, holding constant the various patient characteristics,
medication attributes, and the treatment bundle composition.  Each of the four parameter
estimates is small and insignificantly different from zero; hedonic price indexes computed as anti-
logarithms of these coefficients are 1.049, 1.004, 0.980 and 1.027 for 1992 through 1995,
respectively (1991=1.000).  These quality-adjusted hedonic price indexes are consistent with42
traditional aggregate supply price indexes reported in Table 7 above.  Adjusting for various
patient, medication and treatment changes over time does not appear to affect the central finding
that from 1991 to 1995, there was very little change in the supply price for treating acute phase
major depression.
We now turn to the demand price hedonic equations, whose parameter estimates
appear in the last two columns of Table 9.  In general, the pattern of results from the hedonic
demand price equations involving quality attributes is not as strong and dramatic as is that of the
hedonic supply price equation.  For example, while parameter estimates on the patient’s mental
health comorbidities are of the same sign, in the demand price equation a number are no longer
statistically significant; attributes of the antidepressant medication are not significant as well.  As
with the supply equation, the mental health carve-out coefficient is insignificant.
However, in contrast to the supply price equation, for the demand hedonic price
equation the parameter estimates on the 1992-95 year dummy variables are positive, and by 1994
and 1995 they become statistically significant.  Relative to 1991 = 1.000, holding constant patient
characteristics, medication attributes and treatment composition, the hedonic price indexes for
1992-95 (computed as anti-logs of the estimated parameters) are 1.114, 1.121, 1.155 and 1.443.
Compared to the traditional aggregate demand price indexes reported in Table 8, the time trends
in these hedonic price indexes are broadly similar.  While the traditional aggregate demand price
index in Table 8 averages about 1.30 in 1995, the corresponding hedonic quality-adjusted demand
price index is 1.44; if one takes the antilog of the 1995 parameter estimate in Table 9 minus one
times the robust standard error, one obtains a 1995 price index of about 1.34, not much different
from that in Table 8.  We conclude, therefore, that traditional and hedonic approaches to price
index measurement yield broadly similar results.
IX.  DISCUSSION
Our goal in this research project has been to extend previous research aimed at
constructing CPI- and PPI-like medical price indexes that deal with prices of treatment episodes43
rather than prices of discrete inputs, that are based on transaction rather than list prices, that take
quality changes and expected outcomes into account, and that employ more current expenditure
weights in the aggregation computations.  Although we have made considerable progress in
achieving this goal, we believe a number of caveats are in order.
First, the results reported here differ considerably from those reported earlier in
Frank, Busch and Berndt [1998] and Frank, Berndt and Busch [1998]; there we reported
substantial supply and demand price declines over the 1991-95 time period.  Although we are still
examining why the differences occurred, we believe that the primary difference is that in the new
dataset we bring in many more patients.  The evidence suggests that over time the new data has
an increasing share of patients with: (1) more complicated conditions, (2) greater severity of
illness, and (3) elements of longer term treatments such as continuation phase care.  While the
older dataset may have corresponded with episodes more closely approximating the pristine world
of clinical trials, the larger, new dataset involves patients with more typical complicated illnesses.
It is therefore of interest to examine how robust are our new dataset findings when
one relaxes the strict guideline-compatible standards we imposed in defining episodes of care.  We
have created yet another dataset, where now we relaxed the definitions of the seven bundles.
Bundles which consider drugs alone as treatment remain unchanged at 30-180 days of treatment.
Definitions of bundles which include psychotherapy have been expanded such that the cost of up
to 20 psychotherapy visits is now included in the cost of the episode.  Furthermore, for the
treatment “psychotherapy alone” we previously allowed for a minimum of 5 visits.  This
constraint was relaxed to include episodes treated with 3 or 4 visits.  The appendix table shows
that with the broader definition of standards of care the price indexes are largely unchanged.
Specifically, they are rather flat, not falling below 2 percentage points in comparing 1991 and
1995.
It is also useful to comment on implications of our research findings.  Using
alternative index number procedures, we find that over the 1991-95 time period, the nominal
supply price of acute phase treatment for depression is essentially unchanged, while the real44
supply price (relative to GDP deflator) has declined.  Note that this may well create an upward
bias in estimated price movements for acute phase treatment of depression.  Recall that we
showed that the percentage of episodes meeting guideline standards has increased over time.  The
price indexes reported above do not take account of this apparent move toward the production
frontier.  Improved compliance with standards of care implies greater benefits are being generated
over time, thereby understating price reductions of effective care.  The demand price index
revealed a steady 2-3% per year increase from 1991 to 1994, which is then followed by a sharp
20% increase in 1995.  Since the demand price encompasses only consumers’/patients’ direct
OOPPs expenditures, and since the supply price is the sum of consumer plus insurer payments, it
follows that from 1991 to 1994 there was a steady 2-3% annual decrease in insurers’
expenditures, and that in 1995 a very substantial 20% decrease took place.  While the nominal
supply price of acute phase treatment for depression was apparently unchanged between 1991 and
1995, the compositional burden shifted from third party insurer to patient.  The change in
incidence of payment, in large part due to increased patient copayments and deductibles, likely
reflects efforts by insurers to deal with moral hazard via design of mental health benefits and
tightening of the size of provider networks used in managed care.
Our research findings based on index number procedures are broadly consistent with
those based on simple hedonic price methods, particularly with the supply price.  On the demand
side, the hedonic price index increases more rapidly to 1994, and then increases more sharply in
1995 than do the traditional index numbers.  Note that what we call “traditional” here, however,
represents a substantial departure from current BLS practice, in that we have used as elementary
building blocks the transaction prices accompanying alternative treatment bundles, and not the
(list) prices of fixed set of inputs.  Nevertheless, it is interesting that, as in Berndt, Cockburn and
Griliches [1996], the marginal impact of incorporating hedonic pricing methods is not that
significant, once one defines output quantities carefully.  Our hedonic research could have gone
several steps further, allowing for changing parameters over time and integrating the estimated
hedonic price equations with index number procedures, but we leave those nuances for further45
research.
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Finally, it is worth commenting on implications of this research for procedural
revisions currently under possible consideration at the BLS.  The BLS is responsible for
constructing and publishing PPIs and CPIs for a very large number of medical-related services and
commodities.  Our research has focussed on but one disorder -- major depression -- albeit one
whose output measurement presented considerable challenges.  We believe that economies of
scope and scale are undoubtedly available, and we have experienced a steep learning curve in
working with the MEDSTAT data.  We also believe that extension of the treatment episode
approach to other illnesses and disorders is feasible.  Nevertheless, we are struck by how difficult,
time-consuming and expensive this research has been for us.  If a treatment episode approach is to
be implemented efficiently at the BLS (or elsewhere, such as at HCFA), considerable care needs
to be exercised in choosing a set of illnesses/disorders for which treatment bundles can be well-
defined, for which quality comparisons can readily be made (facilitated by AHCPR or other
published professional guideline standards), and for which claims data can readily be employed.
X.  CONCLUDING REMARKS
A very brief summary of our research is as follows.  We have implemented an
approach that employs transaction data from a publicly available retrospective medical claims data
base of almost half a million lives, annually from 1991 to 1995.  Based on a review of the clinical
research literature dealing with the acute phase of treatment for depression, we identify seven
alternative service bundles that combine varying types and quantities of prescription drugs,
medical management and psychotherapy.  We construct data on episodes of treatment, and their
cost.  Because the treatment bundles are viewed by the medical community as being
therapeutically similar in terms of ex ante efficacy, our linking of treatment bundles provides an
important step toward incorporation of expected medical outcomes.  We distinguish a supply
price index, similar to the BLS’ Producer Price Index, that represents the total receipts received
by providers of medical treatment (from the insurer and the patient), from a demand price index46
(similar to the Consumer Price Index) that incorporates only the out of pocket payments (via
copayments and deductibles) by the patient/consumer.  Finally, we employ a variety of traditional
aggregate index number formulae, consistent with varying assumptions concerning the ex ante
substitutability among the seven treatment bundles, as well as hedonic price procedures in
computing price indexes.
For the supply side price index, the various price indexes all point to a flat and
essentially unchanging price over the 1991-95 time period.  Since the BLS’ various producer price
indexes all indicate a significant increase over the same time period, our results suggest that in real
terms, the supply price for treatment of acute phase depression has fallen over time.  On the
demand side, however, the indexes show a total increase in price of about 10% between 1991 and
1994, and then a very sharp 20% increase.  The usual welfare interpretation of the CPI is not
possible in this case.  The price increase largely reflects increased cost sharing arrangements
which are certain to reduce welfare losses stemming from moral hazard.  This is especially the
case in MEDSTAT data which generally covers plans with substantially lower cost sharing for
mental health care than is typical in the economy as a whole (20% vs. 50%).
Our research can be extended in a number of ways.  Two issues are particularly
important.  First, although we have experimented with use of both strict and somewhat relaxed
guideline criteria to define episodes of care, in each case we have assumed an “all or nothing”
treatment.  The implicit production function therefore involves a steep step or cliff in which
treatment either is or is not effective.  An alternative is to consider some sub-guideline treatment
bundles as having a lower probability of being efficacious than are those meeting guideline
criteria, and therefore to assign the sub-guideline episodes a lower quantity weight.  Together
with a group of clinicians and psychiatric researchers, we are currently initiating an effort to more
completely define the specific depression treatment production function.
Second, we have adhered rather closely to the notion of defining output in terms of
episodes of acute phase treatment.  This involves a somewhat arbitrary delineation of an output
that often does not correspond well to the reality of clinical practice.  Since depression is often a47
chronic recurring illness, continuation and maintenance phase care are part of the overall
treatment of the disorder.  Unfortunately, since the bulk of clinical research has focused on the
acute phase of treatment, our links to outcomes were tied to a somewhat imperfect
characterization of care.  It is therefore important to more completely specify treatment in this
context.
Finally, and perhaps most surprisingly, all of our results point to the fact that given a
budget for treatment of depression, much more could be accomplished in 1995 than in 1991.
That is, real prices of care have fallen.  This runs counter to most public and expert perceptions.
The implications for interpreting spending changes are enormous.  For years the view has been
that spending increases on mental health care (of which depression is 50% in private insurance)
was due to (a) provision of increasing low benefit services, and (b) higher payments to providers.
Our results point to a different story where spending increases are due to a larger number of
“effective” treatments being provided.  These treatments represent a shift towards new treatment
technologies that are provided under a new set of organizational arrangements.
Appendix Table
AGGREGATE PRODUCER (“SUPPLY”) PRICE INDEXES CALCULATED
USING BROADER STANDARD OF CARE DEFINITIONS
Price Index 1991 1992 1993 1994 1995
Fixed Weights:
Laspeyres 1.000 1.015 0.984 0.929 0.997
Paasche 1.000 1.029 1.000 0.968 1.010
Cobb-Douglas 1.000
Chained Weights:
Laspeyres 1.000 1.015 0.981 0.941 0.985
Paasche 1.000 1.017 0.986 0.952 0.993
Fisher Ideal 1.000 1.016 0.983 0.946 0.989
Tornquist 1.000 1.016 0.983 0.946 0.98848
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